Premium
Consequences of treatment withdrawal in type 1 autoimmune hepatitis
Author(s) -
MontanoLoza Aldo J.,
Carpenter Herschel A.,
Czaja Albert J.
Publication year - 2007
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2007.01444.x
Subject(s) - medicine , autoimmune hepatitis , drug withdrawal , hepatitis , gastroenterology , cirrhosis , liver transplantation , drug , adverse effect , hepatitis c , transplantation , psychiatry
Background and Aims: Drug‐related side effects are considered the major consequences of relapse and re‐treatment in patients with autoimmune hepatitis. Our goals were to determine whether relapse is associated with disease progression and whether treatment end points can be refined. Methods: The outcomes of 132 patients with definite type 1 autoimmune hepatitis who had been treated comparably until remission were assessed retrospectively after drug withdrawal. Results: Patients who had relapsed repeatedly after initial treatment withdrawal developed cirrhosis more commonly than patients who sustained remission (18/48 vs 1/22, P =0.004), and those who relapsed once (18/48 vs 2/21, P =0.02). Hepatic death or the need for liver transplantation was also more frequent in the patients who had multiple relapses than those who sustained remission (13/64 vs 0/30, P =0.008) and those who relapsed once (13/64 vs 1/38, P =0.02). Patients who sustained their remission had a higher frequency of normal laboratory indices at drug withdrawal than patients who relapsed (88% vs 46%, P =0.003). Adverse outcomes after relapse did not distinguish patients until after 5 years of observation. Conclusions: Multiple relapses are associated with a poorer prognosis than sustained remission or single relapse episodes. Initial treatment to resolution of laboratory abnormalities may afford the greatest opportunity to prevent relapse.